NVLS Nivalis Therapeutics, Inc.

0  -2%
Previous Close 2.26
Open 2.26
Price To book 0.63
Market Cap 34.76M
Shares 15,656,000
Volume 64,842
Short Ratio 0.44
Av. Daily Volume 372,226

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released November 28, 2016. Primary endpoint not met.
Cystic Fibrosis - two copies of the F508del mutation
Phase 2 data released February 24, 2017 - primary endpoint not met.
Cystic Fibrosis - one copy of the F508del mutation and a second mutation that results in a gating defect in the CFTR protein

Latest News

  1. What's in Store for Nivalis (NVLS) this Earnings Season?
  2. ($$) Alpine Immune Sciences To Go Public Through Reverse Merger With Nivalis
  3. Nivalis' (NVLS) Shares Down After Merger Deal with Alpine
  4. Colorado biotech firm is being acquired to create $90M company in Seattle
  5. Former Dendreon CEO Mitch Gold Returns to Public Biotech Stage with Cancer Immunotherapy Merger
  6. Nivalis Therapeutics, Inc. and Alpine Immune Sciences, Inc. Agree to Combine
  7. Vertex Pharma Cystic Fibrosis Combo Succeeds (VRTX)
  8. Antares Pharma Inc. and Nivalis Therapeutics Inc. Show Resiliency as They Snap Back from Late 2016 Uncertainties
  9. Here’s What Happened With Cyclacel Pharmaceuticals Inc (CYCC) And Nivalis Therapeutics Inc (NVLS)
  10. Nivalis Therapeutics Announces Results from Phase 2 Clinical Trial of Cavosonstat Added to Ivacaftor for Treatment of Cystic Fibrosis
  11. Nivalis Therapeutics reports 4Q loss
  12. Nivalis Therapeutics Reports Fourth Quarter and Full-Year 2016 Financial Results
  13. BioLineRx (BLRX) Starts Cancer Study on BL-8040+Keytruda
  14. Here’s What Happens Now At Nivalis Therapeutics Inc (NVLS)
  15. Colorado biotech to streamline operations, explore alternatives after clinical trial failure
  16. New Strong Buy Stocks for December 30th
  17. These 5 Stocks Under $10 Could Make You a Lot of Money